Projected preventable cancers through full implementation of tobacco control policies in East and South-East Asian countries, 2025–2050: a modeling study
Year: 2026
Type: article
Abstract: Background: To estimate the number of tobacco-related cancer cases that could be prevented if countries in East and South-East Asia achieved the highest level of implementation of the WHO MPOWER policy package (Monitor, Protect, Offer, Warn, Enforce, and Raise). Methods: Based on data from Global Health Observatory and Global Cancer Observatory. We applied fixed-effects linear regression models to examine the association between changes in the national implementation of the MPOWER policies and tobacco smoking prevalence. Population Attributable Fractions (PAFs) for 13 tobacco-related cancers were calculated using Levin's formula under the scenarios of (i) continuation of the current trend, (ii) full implementation of MPOWER. The number of preventable cases (Potential Impact Fraction-PIF) was estimated using the difference in PAFs between the two scenarios. Findings: Between 2025 and 2050, 159 million tobacco-related cancer cases were projected in East and South-East Asian countries, of which 44.2 million (PAF: 27.7%; 95% CI: 25.5-29.9) attributed to current tobacco smoking, including 41.6 million among men (PAF: 42.1%, 95% CI: 39.3-44.8) and 2.6 million among women (PAF: 4.3%, 95% CI: 3.0-5.7). Full implementation of MPOWER was estimated to prevent 3.5 million (95% CI: 2.9-4.0) cancers (PIF: 2.2%, 95% CI: 1.8-2.5). After adjusting for Human Development Index (HDI) variations, preventable cancers decreased to 2.2 million (PIF: 1.4%, 95% CI: 1.2-1.6). Interpretation: Comprehensive implementation of MPOWER policies could substantially reduce the future cancer burden in East and South-East Asian countries. Funding: None.
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,250
Funders: National Science Foundation, Pfizer, AstraZeneca, World Health Organization, Gilead Sciences, Infectious Diseases Society of America, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, American College of Veterinary Internal Medicine, CSL Behring, Deutsches Zentrum für Infektionsforschung, Sunovion, HELIOS Kliniken, Cidara Therapeutics, Public Health Agency of Canada, Jazz Pharmaceuticals, Joint Programming Initiative on Antimicrobial Resistance, McGill University Health Centre, Mylan, Moderna, Glenmark Pharmaceuticals, Association of Medical Microbiology and Infectious Disease Canada, National Institute for Health and Care Research, Dowager Countess Eleanor Peel Trust, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Astellas Pharma, Shionogi, Ludwig-Maximilians-Universität München, Universität zu Köln, Merck Canada, National Institutes of Health, Directorate for Biological Sciences, Pfizer Japan, Pfizer Canada, Sanofi Pasteur, Manchester Biomedical Research Centre, Canadian Institutes of Health Research, Instituto de Salud Carlos III, National Institute of Allergy and Infectious Diseases, Janssen Pharmaceuticals
Awards: G1483213741, G1798610363, G5755041744
OpenAlex ID: W7203830454
